Meliorate Inc., North Weymouth, MA, 02191, USA.
BMC Res Notes. 2020 May 24;13(1):254. doi: 10.1186/s13104-020-05103-4.
UHRF1 is a multi-domain protein that recognizes both histone and DNA modification marks on chromatin. UHRF1 is involved in various cellular processes that lead to tumorigenesis and thus attracted considerable attention as a potential anti-cancer drug target. The SRA domain is a unique to the UHRF family. SRA domain recognizes 5-methylcytosine in hemimethylated DNA and necessary for maintenance DNA methylation mediated by DNMT1. Small molecules capable of interacting with the SRA domain may reduce aberrant methylation levels by preventing the interaction of 5-methylcytosine with the SRA domain and thereby blocking substrate access to the catalytic center of DNMT1. The data were collected to identify and predict an initial set of small molecules that are expected to bind to the SRA domain.
Nearly 2.4 million molecules from various chemical libraries were screened with the SRA domain of UHRF1 using Schrodinger's Small Molecule Drug Discovery Suite. The data is available in the form of a methodology presentation, MS Excel files listing the top hits, and Maestro pose viewer files that provide visualization of how the identified ligands interact with the SRA domain.
UHRF1 是一种具有多种结构域的蛋白,能够识别组蛋白和 DNA 修饰标记。UHRF1 参与多种导致肿瘤发生的细胞过程,因此作为一种潜在的抗癌药物靶点引起了相当大的关注。SRA 结构域是 UHRF 家族所特有的。SRA 结构域识别半甲基化 DNA 中的 5-甲基胞嘧啶,并且对于由 DNMT1 介导的 DNA 甲基化维持是必需的。能够与 SRA 结构域相互作用的小分子可能通过防止 5-甲基胞嘧啶与 SRA 结构域的相互作用,从而阻止底物进入 DNMT1 的催化中心,从而降低异常甲基化水平。这些数据是为了识别和预测一组有望与 SRA 结构域结合的初始小分子而收集的。
使用 Schrödinger 的小分子药物发现套件,对来自各种化学文库的近 240 万个分子进行了 UHRF1 的 SRA 结构域筛选。数据以方法介绍、列出顶级命中的 MS Excel 文件以及提供识别配体与 SRA 结构域相互作用方式的 Maestro 配体查看器文件的形式提供。